Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a pilot study assessing efficacy and safety in patients with advanced prostate cancer.
PAE has been shown to be safe and effective in the treatment of prostatic bleeding and lower urinary tract symptoms arising from bladder outlet obstruction.
Advanced (defined as locally advanced, metastatic or both in this study) PCA is frequently associated with both of these conditions. The currently most frequently performed palliative surgical treatment is TURP. Though performed endoscopically, TURP is associated with significant side effects in this setting. PAE has been shown to have a superior side-effect profile in the treatment of bladder outlet obstruction compared to TURP.
In addition, there is growing evidence that patients with advanced PCA might benefit from cytoreductive therapy (e.g. radical prostatectomy or external beam radiation therapy). However, recent methods of cytoreductive treatment of PCA hold the risk of being highly invasive and are associated with severe side effects. PAE might represent a minimally invasive alternative in this setting.
Therefore, efficacy and safety of PAE in patients with advanced prostate cancer is assessed in this pilot-study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Prostatic Artery Embolization (PAE) | Other | PAE performed under local anesthesia using officially approved microspheres. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Prostatic Artery Embolization | Device | PAE is performed under local anesthesia using commercially available and approved microspheres (study is not limited to a specific manufacturer or product). |
| Measure | Description | Time Frame |
|---|---|---|
| Reduction of Lower Urinary Tract Symptoms | Change of total score of International Prostate Symptoms Score (IPSS; range 0 points (no symptoms) to 35 points (severe symptoms)) | Baseline and 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Reduction of Lower Urinary Tract Symptoms | Change of total score of International Prostate Symptoms Score (IPSS; range 0 points (no symptoms) to 35 points (severe symptoms)) | Baseline and 6 weeks |
| Reduction of Lower Urinary Tract Symptoms |
Not provided
Inclusion Criteria
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Dominik Abt, MD | Contact | +41714941418 | dominik.abt@kssg.ch |
| Name | Affiliation | Role |
|---|---|---|
| Dominik Abt, MD | St. Gallen Cantonal Hospital, Dept. of Urology, Rorschacherstrasse 95, 9007 St. Gallen | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cantonal Hospital St. Gallen | Recruiting | Sankt Gallen | Canton of St. Gallen | 9007 | Switzerland |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38416176 | Derived | Burkhardt O, Abt D, Hechelhammer L, Kim O, Omlin A, Schmid HP, Engeler D, Zumstein V, Mullhaupt G. Prostatic Artery Embolization in Patients with Advanced Prostate Cancer: A Prospective Single Center Pilot Study. Cardiovasc Intervent Radiol. 2024 Jun;47(6):771-782. doi: 10.1007/s00270-024-03679-z. Epub 2024 Feb 28. |
Not provided
Not provided
Decision will be made individually up on request and based on approval by our local ethics committee.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| D001748 | Urinary Bladder Neck Obstruction |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Change of total score of International Prostate Symptoms Score (IPSS; range 0 points (no symptoms) to 35 points (severe symptoms))
| Baseline and 6 months |
| Reduction of Lower Urinary Tract Symptoms | Change of total score of International Prostate Symptoms Score (IPSS; range 0 points (no symptoms) to 35 points (severe symptoms)) | Baseline and 12 months |
| Occurrence of macroscopic hematuria | Assessment of occurrence of hematuria according to CTCAE v.4.03 classification | From time of PAE to study completion (1 year) |
| Reduction of Prostate symptoms | Change of CPSI total score (Chronic prostatitis symptoms score; range 0 points (no symptoms) to 43 points (severe symptoms)) | baseline and 6 weeks |
| Reduction of Prostate symptoms | Change of CPSI total score (Chronic prostatitis symptoms score; range 0 points (no symptoms) to 43 points (severe symptoms)) | baseline and 12 weeks |
| Reduction of Prostate symptoms | Change of CPSI total score (Chronic prostatitis symptoms score; range 0 points (no symptoms) to 43 points (severe symptoms)) | baseline and 6 months |
| Reduction of Prostate symptoms | Change of CPSI total score (Chronic prostatitis symptoms score; range 0 points (no symptoms) to 43 points (severe symptoms)) | baseline and 12 months |
| Occurrence of urinary incontinence | Assessment of ICS-SF questionnaire | 6 week after PAE |
| Occurrence of urinary incontinence | Assessment of ICS-SF questionnaire | 12 week after PAE |
| Occurrence of urinary incontinence | Assessment of ICS-SF questionnaire | 6 months after PAE |
| Occurrence of urinary incontinence | Assessment of ICS-SF questionnaire | 12 months after PAE |
| Changes of free urinary flow rate | Measurement of urinary stream (mL/s) by urinary flow rate measurement | Baseline and 6 weeks |
| Changes of free urinary flow rate | Measurement of urinary stream (mL/s) by urinary flow rate measurement | Baseline and 12 weeks |
| Changes of free urinary flow rate | Measurement of urinary stream (mL/s) by urinary flow rate measurement | Baseline and 6 months |
| Changes of free urinary flow rate | Measurement of urinary stream (mL/s) by urinary flow rate measurement | Baseline and 12 months |
| Changes of post void residual urine | Measurement of post void residual urine (mL) by transabdominal ultrasound | Baseline and 6 weeks |
| Changes of post void residual urine | Measurement of post void residual urine (mL) by transabdominal ultrasound | Baseline and 12 weeks |
| Changes of post void residual urine | Measurement of post void residual urine (mL) by transabdominal ultrasound | Baseline and 6 months |
| Changes of post void residual urine | Measurement of post void residual urine (mL) by transabdominal ultrasound | Baseline and 12 months |
| Rate of local reinterventions | Assessment of number and type of reinterventions for prostate and bladder problems | During 1 year study period |
| Intraoperative Adverse Events | Assessment of adverse events that are at least possibly related to study procedure according to Clavien-Dindo and CTCAE | While PAE is performed (intra-operatively) |
| Adverse Events | Assessment of adverse events that are at least possibly related to study procedure according to Clavien-Dindo and CTCAE | 6 weeks after PAE |
| Adverse Events | Assessment of adverse events that are at least possibly related to study procedure according to Clavien-Dindo and CTCAE | 12 weeks after PAE |
| Adverse Events | Assessment of adverse events that are at least possibly related to study procedure according to Clavien-Dindo and CTCAE | 6 months after PAE |
| Adverse Events | Assessment of adverse events that are at least possibly related to study procedure according to Clavien-Dindo and CTCAE | 12 months after PAE |
| Feasibility of PAE | Possibility of successful completion of PAE in the study cohort defined by compete stasis of blood flow in the prostate | While PAE is performed (intra-operatively) |
| Estimation of tumor burden | Changes of Prostate Specific Antigen | Baseline and 24h after PAE |
| Estimation of tumor burden | Changes of Prostate Specific Antigen | Baseline and 6 weeks after PAE |
| Estimation of tumor burden | Changes of Prostate Specific Antigen | Baseline and 12 weeks after PAE |
| Estimation of tumor burden | Changes of Prostate Specific Antigen | Baseline and 6 months after PAE |
| Estimation of tumor burden | Changes of Prostate Specific Antigen | Baseline and 12 months after PAE |
| Estimation of tumor volume | Change of tumor volume calculated by magnetic resonance imaging | Baseline and 12 weeks after PAE |
| Prostate volume | Change of prostate volume calculated by magnetic resonance imaging | Baseline and 12 weeks after PAE |
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
| D014524 | Urethral Obstruction |
| D014522 | Urethral Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D001745 | Urinary Bladder Diseases |